William Goolsbee - Sarepta Therapeutics Non-Executive Independent Chairman of the Board
| AB3A Stock | EUR 114.70 2.45 0.00% |
Chairman
Mr. William A. Goolsbee is NonExecutive Independent Director of Sarepta Therapeutics Inc. He also serves as a member of the audit committee and the compensation committee. Mr. Goolsbee was founder chairman and Chief Executive Officer of Horizon Medical Inc. from 1987 until its acquisition by a unit of UBS Private Equity in 2002. Mr. Goolsbee was a founding director of ImmunoTherapy Corporation in 1993 and became chairman of the board of directors in 1995 a position he held until overseeing the successful acquisition of ImmunoTherapy by Sarepta Therapeutics Inc. in 1998. His experience prior to 1987 includes a series of increasingly responsible executive positions with CooperVision Inc. and Cooper Laboratories Inc. Mr. Goolsbee holds a B.A. degree from the University of California at Santa Barbara. Mr. Goolsbee served as Chairman of privately held BMG Pharma LLC a pharmaceutical company from 2006 through 2011 and presently serves as Chairman and Chief Executive Officer of BMG Hematology LLC a product development and licensing company. Our nominating and corporate governance committee believes that Mr. Goolsbees 30year career in the medical device and biopharmaceutical industries qualifies him for service as a member of the Board. since 2014.
| Age | 60 |
| Tenure | 10 years |
| Phone | 617 274 4000 |
| Web | https://www.sarepta.com |
Sarepta Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1149) % which means that it has lost $0.1149 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.591) %, meaning that it generated substantial loss on money invested by shareholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 1.1 B in total debt with debt to equity ratio (D/E) of 44.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sarepta Therapeutics has a current ratio of 8.63, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Sarepta Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Sarepta Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sarepta Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sarepta to invest in growth at high rates of return. When we think about Sarepta Therapeutics' use of debt, we should always consider it together with cash and equity.
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts. SAREPTA THERAP operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 499 people. Sarepta Therapeutics (AB3A) is traded on Frankfurt Exchange in Germany and employs 840 people. Management Performance
| Return On Equity | -1.59 | |||
| Return On Asset | -0.11 |
Sarepta Therapeutics Leadership Team
Elected by the shareholders, the Sarepta Therapeutics' board of directors comprises two types of representatives: Sarepta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sarepta. The board's role is to monitor Sarepta Therapeutics' management team and ensure that shareholders' interests are well served. Sarepta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sarepta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Kaye, Senior Vice President Chief Medical Officer | ||
| Alexander Cumbo, Vice President Head of Commercial | ||
| William Ciambrone, Ex Operations | ||
| Dallan Murray, VP Officer | ||
| Hans Wigzell, Independent Director | ||
| Michael Bonney, Director | ||
| Sandesh Mahatme, CFO, Senior Vice President Chief Accounting Officer | ||
| Jayant Aphale, Senior Vice President - Technical Operations | ||
| Mary Gray, Director | ||
| Douglas Esq, CEO Pres | ||
| Anthony Chase, Independent Director | ||
| Douglas Ingram, President CEO | ||
| Gilmore ONeill, Senior Vice President Chief Medical Officer | ||
| JeanPaul Kress, Director | ||
| Joan Wood, Vice President - Human Resources | ||
| Alison Nasisi, Chief VP | ||
| Bilal Arif, VP Operations | ||
| Ryan Brown, Gen VP | ||
| Richard Barry, Independent Director | ||
| Gil Price, Independent Director | ||
| Catherine StehmanBreen, Senior Vice President Chief Medical Officer | ||
| David Howton, Senior Vice President General Counsel, Corporate Secretary | ||
| Mary Jenkins, Sr Relations | ||
| Ian Estepan, Ex CFO | ||
| Guriqbal Basi, Senior Vice President Chief Scientific Officer | ||
| William Goolsbee, Non-Executive Independent Chairman of the Board | ||
| Louise RodinoKlapac, Chief VP | ||
| Claude Nicaise, Independent Director | ||
| Kathleen Behrens, Independent Director | ||
| Diane Berry, Sr Affairs | ||
| Erin Cox, IR Contact | ||
| Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality |
Sarepta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sarepta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.59 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.82) % | |||
| Operating Margin | (0.61) % | |||
| Current Valuation | 10.05 B | |||
| Shares Outstanding | 87.78 M | |||
| Shares Owned By Insiders | 4.39 % | |||
| Shares Owned By Institutions | 90.25 % | |||
| Price To Earning | (18.35) X | |||
| Price To Book | 24.76 X |
Pair Trading with Sarepta Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sarepta Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sarepta Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Sarepta Stock
| 0.45 | 0QF | Moderna Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Sarepta Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sarepta Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sarepta Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sarepta Therapeutics to buy it.
The correlation of Sarepta Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sarepta Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sarepta Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sarepta Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.Note that the Sarepta Therapeutics information on this page should be used as a complementary analysis to other Sarepta Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |